Replimune Group, Inc. current report, 11 August 2020

Full document

Business Context and Reporting Period

Replimune Group, Inc. filed this Form 8-K on August 11, 2020, regarding a new at-the-market equity offering and termination of its prior offering agreement. The filing does not report quarterly or annual operating results.

Material Financing and Financial Metrics

  • Replimune entered into a Sales Agreement with SVB Leerink LLC allowing it to sell, at its option, up to $75.0 million of common stock from time to time.
  • Sales may occur through an at-the-market offering or, if authorized, negotiated transactions, subject to the effectiveness of the company’s Form S-3 registration statement.
  • SVB Leerink may receive commissions of up to 3.0% of gross proceeds from any sales.
  • The company provided customary indemnification to the agent.
  • The filing does not provide current revenue, profit or loss, cash flow, margins, debt, cash balance, or liquidity figures.

Changes Versus the Prior Comparable Arrangement

  • The new Sales Agreement replaced and terminated the August 8, 2019 sales agreement.
  • The prior agreement initially authorized up to $75.0 million of common-stock sales, later reduced in June 2020 to $30.0 million.
  • Under the prior 2019 ATM Program, Replimune sold 287,559 shares for approximately $4.6 million of net proceeds.
  • No additional shares may be sold under the terminated 2019 ATM Program.

Outlook, Risks, and Unusual Items

  • The company stated that it may, but is not obligated to, issue shares under the new Sales Agreement; therefore, the timing and amount of future proceeds are uncertain.
  • Any equity issuance could provide funding but may dilute existing stockholders.
  • The new program is subject to registration and applicable securities-law requirements.
  • The related Form S-3 permits registration of up to $350.0 million of various securities, including common and preferred stock, debt securities, warrants, and units; the filing does not indicate that the full amount will be issued.
  • The filing contains no operating guidance or management forecast.

Investor Verification Items

  • Verify whether and when Replimune sells shares under the new $75.0 million ATM facility.
  • Confirm gross proceeds, commissions, net proceeds, and the resulting share-count dilution from any future sales.
  • Review the Form S-3 and Sales Agreement for offering terms, limitations, and remaining registered capacity.
  • Assess the company’s cash needs and liquidity using its latest periodic filing, as this Form 8-K provides no current balance-sheet or cash-flow data.